CROSSJECT enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO® Methotrexate in India

Chenôve (France) and Bangalore (India), September 14 2015 – 

CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) , the creator of ZENEO®, a needle-free injection system developed to be used with a portfolio of well-known drugs announces today a partnering agreement with Sayre Therapeutics to commercialise ZENEO® Methotrexate in India. The filing of the marketing authorisation files of this innovative product for the treatment of rheumatoid arthritis in the region, is anticipated early 2017.

Crossject InjectThe agreement provides Sayre Therapeutics with exclusive distribution and marketing rights in India, Bangladesh, Sri Lanka and Nepal. In return, CROSSJECT will receive a share from 20% to 40% of the revenues generated from the product. Sayre Therapeutics has committed to minimum levels of volumes and marketing investment.

Patrick Alexandre, CROSSJECT’s founder and CEO said: “The Indian market has been chosen due to the pricing environment which will allow us to generate attractive returns. This is a high margin niche market thanks to the free pricing mechanisms in this area. This deal will allow us to capture value from ZENEO® without any further investments. It also allows us to continue to focus our commercial strategy on North America and Europe. We are convinced that Sayre Therapeutics with its entrepreneurial spirit, experienced team, including its sales force, has all the attributes needed to successfully commercialise ZENEO® Methotrexate.”

A spokesperson for Sayre Therapeutics comments: “This collaboration with CROSSJECT will further reinforce our product portfolio, particularly for the home care market. Sayre Therapeutics is now well established through the Indian subcontinent and South Asia, and we are now ready to focus on chronic diseases such as rheumatoid arthritis by providing patients with a needle-free injection system that is easy and safe to use.”

About Crossject •

Crossject is using its world-leading needle-free injection system, ZENEO™ to develop an attractive pipeline of high-value SUPERGENERICS or New Therapeutics Entities. These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort. Crossject’s needle-free, pre-filled, single-use ZENEO ™ injection systems are unique in that they can be tailored to deliver drugs intradermally, subcutaneously and intramuscularly. This means that ZENEO™ can allow a wide range of drugs and vaccines for a broad range of indications to be developed and approved in a very short period. Outside its own portfolio of SUPERGENERICS, Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

CROSSJECT is listed on Alternext Paris (Mnemo : ALCJ, ISIN : FR0011716265)

About Sayre Therapeutics

Sayre Therapeutics is specialized in innovative treatments and medical devices commercialization in South Asia. The founders experience and its dynamic team have allowed Sayre to rapidly develop its product portfolio.

Follow us on Twitter @Crossject


Crossject                                                                          Citigate Dewe Rogerson

Patrick Alexandre / Timothée Muller                           Laurence Bault/Lucie Larguier                                                        +33 (0) 1 53 32 84 78/ 84 75

Sayre Therapeutics

+91 80 41137692


To read from the source: Click here 

BMG PHARMA S.r.l. Announces the Signature of a Distribution Agreement for its Cancer Supportive Care Line Including its Iron in Liposomal Technology Based Product With Sayre Therapeutics for India and Other Asian Area Countries

MILAN, Italy, July 31, 2015 /PRNewswire/ —

BMG Pharma S.r.l. is pleased to announce the signature of a Distribution

BMG Pharma

BMG Pharma

Agreement with Sayre Therapeutics Ltd,Bangalore, India,  for its cancer supportive products under the brand name GelX® and for its liposomal iron based food supplement  IronOne.

Thanks to its innovative formulas, the GelX®  range alleviates pain in oncological patients, offering different solutions for chemotherapy & radiation induced oral mucositis, xerostomia, dry mouth and radiation dermatitis.

IronOne is a new  iron concept, available in softgel  capsules, utilizing a unique coating technology in liposomes to create a product, which allows the molecule to pass through the stomach, avoiding gastrointestinal irritation. This means that the iron is absorbed directly through the lining of the gastrointestinal tract, proving it extremely effective,

“We are proud to cooperate with Sayre who we have signed up with as our preferred and exclusive partner in achieving registration & distribution of the products in their territory” – said Marco Mastrodonato, CEO of BMG Pharma S.r.l. – “We are pleased to offer our products to allow patients to receive the best care possible by using innovative formulations to provide fast pain relief for oncologic and anemic  patients  “This partnership is a major milestone for BMG as it allows our company to enter the Indian and south Asian  market and we are sure that Sayre will implement strong strategies in order to support the distribution of our products in all these markets”.

A Sayre spokesperson said “Our collaboration with BMG Pharma S.r.l. provides a tremendous boost to our efforts to bring cutting-edge cancer supportive care products to the Indian subcontinent. Sayre is committed to making available life-saving medicines in South Asia, to benefit the patient community and improve their quality of life.” “We are thrilled to partner with BMG Pharma S.r.l. to fulfill a high unmet need segment and explore newer therapies in cancer in the future.

About SAYRE:

M/S Sayre Therapeutics Private Ltd. is South Asia’s only integrated platform for disease management backed by a unique distribution and commercialization model for novel and / or differentiated drugs, companion diagnostics and drug-delivery devices in the super-specialty areas of Oncology and Immunology. Companies with novel Oncology and Immunology assets can work with us in South Asia, as we focus on alleviating life-threatening diseases with high unmet need.

For press releases and other company information, visit:

Contact: Ms. Chandana Balasubramanian,

About  BMG Pharma S.r.l.

BMG Pharma S.r.l. is a specialty pharmaceutical company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

The Company’s key features are:

  • Full involvement in business and partnering    
  • Presence in  different therapeutic areas
  • Specific regulatory strategies for each product as Prescription and OTC Medical Devices in EC and US to allow rapid market introduction. BMG focuses on bringing products to market quickly with supportive clinical data.
  • IP protection for most of the products and technologies.

For press releases and other company information, visit:

Contact: Mrs. Loredana Galli,, +39-3385706413


To read from the source find the link below: Click Here